AltPep provides a novel approach for tackling amyloid diseases, with diagnostic, therapeutic and anti-biofilm applications.
AltPep has raised $52.9M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
AltPep's investors include S32, Eli Lilly, Alexandria Venture Investments, Senator Investment Group, Partners Investment.
AltPep is headquartered in Seattle, United States.
AltPep provides a novel approach for tackling amyloid diseases, with diagnostic, therapeutic and anti-biofilm applications.
AltPep is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"AltPep — Funding & Investors." VCBacked, June 22, 2023, https://www.vcbacked.co/company/altpep. Accessed October 27, 2026.
VCBacked. (2023). AltPep — Funding & Investors. Retrieved October 27, 2026, from https://www.vcbacked.co/company/altpep
{{cite web |title=AltPep — Funding & Investors |url=https://www.vcbacked.co/company/altpep |website=VCBacked |access-date=October 27, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated